Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer is a phase 2 interventional study registered as NCT06463028 by Faeth Therapeutics, with 40 participants planned, started 2024-12-12 and due to reach its primary completion in 2028-09. Interventions recorded: Sapanisertib, Serabelisib, Paclitaxel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.